Belgian clinical-stage biopharmaceutical firm ASIT Biotech has reported positive results from its Phase III clinical trial of gp-ASIT+ for the treatment of patients with grass pollen-induced allergic rhinitis.

gp-ASIT+ is a product candidate containing a mixture of natural allergen fragments extracted from a purified specific proteinic extract of Lolium perenne pollen.

The natural peptides are comprised of multiple epitopes that stimulate the immune system with optimal complexity.

The results indicated that the product has improved clinical symptoms and minimised the use of medication in allergic rhinitis patients by 15%-21% when compared to placebo.

The randomised Phase III trial was conducted in 554 patients in 67 clinical centres within Belgium, Czech Republic, France, Germany, Italy and Spain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“As described in the IPO prospectus, we will explore additional financial opportunities to develop new ASIT+ products.”

ASIT biotech chief executive officer Thierry Legon said: “This study confirms the effectiveness of our gp-ASIT+ grass pollen product, and we are looking forward to discussing the detailed results with regulatory agencies in Germany and the US to determine a clear pathway to further clinical development and marketing authorisation.

“Furthermore, the finding of the mechanism of action further supports the development of the ASIT+ product portfolio targeting house dust mite, ragweed and food allergies. As described in the IPO prospectus, we will explore additional financial opportunities to develop new ASIT+ products.”

The primary endpoint measured as the mean combined clinical symptom and medication (CSMS) score during the peak pollen period was found to be consistent with the results obtained during the entire pollen period.

It was also found that gp-ASIT+ triggers grass pollen allergen-specific IgG4 and blocks antibodies, in addition to having good overall tolerability.

Image: Pollen from grass. Photo: courtesy of Unsplash / Wikipedia.